Elevar Therapeutics and Inceptua partner to commercialize Apealea®

By Akshay Kedari  | Date: 2020-12-29

Elevar Therapeutics and Inceptua partner to commercialize Apealea®

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel treatment Apealea® in Europe. 

For the uninitiated, Elevar Therapeutics is a Utah-headquartered organization that focuses on offering medical services to patients who have inadequate or limited therapeutic options. Their patent treatment Apealea® is a water-soluble, intravenously injectable chemotherapy agent that is primarily used to treat ovarian cancer as well as other solid tumors.

Reportedly, the recent collaboration is aimed at leveraging Inceptua’s capabilities in oncology development as well as orphan treatments to strengthen the presence of Apealea® in the European market and optimize the value of its portfolio on a global level.

As per the contract, Inceptua will be granted exclusive rights for the distribution and commercialization of the drug across Europe. However, these rights do not permit the administration in Nordic countries including Iceland, Sweden, Norway, Finland, and Denmark.

Stefan Fraenkel, Chief Executive Officer of Inceptua, was reported saying that the company has observed great potential in Apealea® for treatment of ovarian cancer among patients who have a low tolerance for paclitaxel formulated with cremophor. The organization’s established sales force, vast market access capabilities, and robust distribution networks will bolster the commercialization of the treatment throughout Europe, he added.

It is to be noted that Apealea® was granted marketing authorization by regulatory authorities for its administration in the European Economic Area in November 2018, in combination with carboplatin for treating adult patients diagnosed with platinum-sensitive epithelial ovarian cancer. The treatment has recently been granted Orphan Drug Designation by the U.S. FDA (Food and Drug Administration), as cited by credible sources.

About Inceptua Group

Established in 1997, Inceptua focuses on delivering products and services for clinical trials and providing medication for various patient programs. The company’s primary objectives include offering customer-centric services at all stages of a drug lifecycle, facilitating access to unlicensed medicines, and providing an international commercialization platform for pharmaceutical as well as biopharmaceutical products.  

Source credits –

https://www.prnewswire.com/news-releases/elevar-therapeutics-announces-licensing-agreement-with-inceptua-group-for-commercialization-of-apealea-paclitaxel-micellar-in-europe-301198507.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Bayer sells environmental science biz to Indian firm for $13.5 million

Bayer sells environmental science biz to Indian firm for $13.5 million

By Akshay Kedari

German multinational pharmaceutical and biotechnology company, Bayer CropScience recently stated that its board has given the go-ahead for selling its Environmental Science Business to 2022 ES Discovery India, a private Indian company. The deal wi...

Stockly to raise another $12M to expand its operations & employee base

Stockly to raise another $12M to expand its operations & employee base

By Akshay Kedari

French-based software startup, Stockly is reportedly raising another $12 million (€12 million) in a Series A round from Daphni, Eurazeo, and several other business angels. Apparently, the firm pools together the inventory of several e-commerc...

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

Alipay+ allies with Asian E-Wallets to boost cashless travel in South Korea

By Akshay Kedari

Amidst rising efforts for promoting cashless travel, prominent mobile payment providers in Asia have recently announced an integration of the cross-border digitalized payment solutions from Alipay+ in South Korea. With this move, users of e-wallet...

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

Seracle, Sumsub partner for offering enhanced KYC protocols and cybersecurity

By Akshay Kedari

Sumsub will assist Seracle in building an innovative blockchain ecosystem Sumsub will offer enhanced security to Seracle at a time when losses due to cryptocurrency thefts have increased by about 60% to $1.9 billion Seracle, a global blockc...

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

CATL unveils new Module to Bracket tech for heavy-duty electric trucks

By Akshay Kedari

CATL, a Chinese battery manufacturer and technology company, has reportedly introduced a new battery technology known as Module to Bracket (MTB) for heavy-duty electric trucks. As per reliable sources, the MTB technology deploys the battery module...